Sociedad Americana de Hirudoterapia

Prevalence, etiology, and transmission of fibropapillomatosis in Olive Ridley turtles at a mass-nesting colony in the Mexican Pacific

Vector-host study published in PLoS ONE (2026)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Seguridad y control de infeccionesLabastida-Estrada E et al. · PloS one, 2026

Abstract

Fibropapillomatosis (FP) is a widespread disease in sea turtles characterized by the development of internal and external tumors that hinder physiological and general functions. Chelonid alphaherpesvirus 5 (ChAHV5) is recognized as the causative agent and has been studied and characterized worldwide. Here, we evaluated the prevalence and severity of FP in olive ridley females (Lepidochelys olivacea) during the mass-nesting season from July 2022 to January 2023 at Playa Escobilla, Oaxaca, on the Mexican Pacific coast. Using fragments of the capsid protein (UL18) and DNA polymerase (UL30) genes, we assessed the molecular detection of viral DNA in tumors and healthy tissues from FP-affected and apparently healthy females. To explore the potential role of the marine leech Ozobranchus branchiatus as a vector, we also screened leeches collected from both FP-affected and healthy turtles for viral DNA. Additionally, we identified ChAHV5 genetic variants from UL18 and UL30 sequences obtained from turtles and leeches. The estimated FP prevalence was 1.05%. Among the 62 FP-affected females, 82% were classified as mild, 13% as moderate, and 5% as severe. Molecular detection using the UL30 marker achieved a 100% detection rate in FP-affected turtles and 91% in apparently healthy individuals. In contrast, viral DNA was detected in only 6% of the analyzed leeches. Based on UL18, we identified a novel variant exclusive to olive ridley turtles (UL18_haplotype 3), while six UL30 variants were recorded, with UL30_Var01 being the most abundant and widely distributed in the Pacific. The low detection rate of ChAHV5 in leeches does not support their role as vectors. Our findings provide critical evidence of latent viral presence and highlight the need for integrating molecular surveillance in nesting sites to improve our understanding of FP dynamics and its potential impact on sea turtle conservation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsTurtlesFemaleMexicoPrevalenceDNA, ViralAlphaherpesvirinaePapillomaPhylogenyHerpesviridae Infections

Resumen

Large mass-nesting study of olive Ridley turtles assessing fibropapillomatosis prevalence and ChHV5 detection in leeches (Ozobranchus branchiatus) — finds low leech detection rate, weak vector role.

Por qué esto importa para la hirudoterapia

This study evaluated fibropapillomatosis (FP) prevalence and chelonid alphaherpesvirus 5 (ChAHV5) detection in olive ridley turtles (Lepidochelys olivacea) during mass-nesting at Playa Escobilla, Oaxaca, Mexico (July 2022–January 2023). FP prevalence was estimated at 1.05%; viral DNA was detected in 100% of FP-affected turtles and 91% of apparently healthy individuals using the UL30 marker, but in only 6% of screened Ozobranchus branchiatus leeches. The authors concluded the low leech detection rate does not support leeches as ChAHV5 vectors. This study is relevant only to sea turtle disease ecology and has no connection to medicinal hirudotherapy or the therapeutic leech secretome.

Citación

Prevalence, etiology, and transmission of fibropapillomatosis in Olive Ridley turtles at a mass-nesting colony in the Mexican Pacific.

Labastida-Estrada E et al. · PloS one, 2026

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.